Skip to content

Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function

Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function: a 12 Week, Randomized Double-blind, Placebo-controlled Clinical Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01734200
Enrollment
80
Registered
2012-11-27
Start date
2012-11-30
Completion date
2013-11-30
Last updated
2015-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Function

Brief summary

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Eriobotyra Japonica Lindley Extract on improvement of Memory Function. The investigators measured decrement of improvement of Memory Function, including K-MMSE, Rey-Kim Memory Test, BCRS, and PRMQ, and monitored their blood pressure.

Interventions

Eriobotyra Japonica Lindley Extract (1.5g/day)

DIETARY_SUPPLEMENTPlacebo

Placebo (1.5g/day)

Sponsors

Chonbuk National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
16 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and females 16-19 years old * Weight within ±30% of ideal body weight * Able to give informed consent

Exclusion criteria

* Allergic or hypersensitive to any of the ingredients in the test products * History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery * History of alcohol or substance abuse * Participation in any other clinical trials within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * Pregnant or lactating women etc.

Design outcomes

Primary

MeasureTime frameDescription
Changes in K-MMSE(Korean Mini-Mental State Examination)12 weeksK-MMSE(Korean Mini-Mental State Examination) was measured in study visit 1(0 week) and visit 3(12 week).

Secondary

MeasureTime frameDescription
Changes in Rey-Kim Memory Test12 weeksRey-Kim Memory Test was measured in study visit 1(0 week) and visit 3(12 week).
Changes in BCRS(Brief Cognitive Rating Scale)12 weeksBCRS(Brief Cognitive Rating Scale) was measured in study visit 1(0 week) and visit 3(12 week).
Changes in PRMQ(Prospective and retrospective memory questionnaire)12 weeksPRMQ(Prospective and retrospective memory questionnaire) was measured in study visit 1(0 week) and visit 3(12 week).
Changes in STAI(State-trait anxiety inventory)12 weeksSTAI(State-trait anxiety inventory) was measured in study visit 1(0 week) and visit 3(12 week).
Changes in BDNF(Brain derived neurotrophic factor)12 weeksBDNF(Brain derived neurotrophic factor) was measured in study visit 1(0 week) and visit 3(12 week).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026